Brokerages Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Price Target at $11.56

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has earned a consensus rating of “Buy” from the ten ratings firms that are presently covering the firm, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $11.56.

Several brokerages recently issued reports on TLSI. Lake Street Capital initiated coverage on TriSalus Life Sciences in a report on Thursday, February 13th. They issued a “buy” rating and a $10.00 price target for the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday. Roth Mkm reiterated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday, January 24th. Finally, Cantor Fitzgerald started coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target for the company.

TriSalus Life Sciences Price Performance

NASDAQ TLSI opened at $5.62 on Tuesday. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $10.42. The firm has a market capitalization of $171.37 million, a P/E ratio of -2.26 and a beta of 0.48. The business’s 50-day simple moving average is $5.40 and its 200-day simple moving average is $4.73.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.35) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.35). The business had revenue of $8.26 million for the quarter, compared to analyst estimates of $8.12 million. On average, equities research analysts expect that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Insider Activity

In other news, CEO Mary T. Szela acquired 4,826 shares of the business’s stock in a transaction on Monday, January 27th. The shares were purchased at an average price of $5.42 per share, for a total transaction of $26,156.92. Following the completion of the purchase, the chief executive officer now directly owns 429,503 shares of the company’s stock, valued at $2,327,906.26. This represents a 1.14 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James Emmett Young bought 6,000 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The stock was purchased at an average price of $5.65 per share, with a total value of $33,900.00. Following the transaction, the chief financial officer now owns 30,000 shares in the company, valued at approximately $169,500. This represents a 25.00 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders acquired 54,856 shares of company stock worth $294,608. 32.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in TriSalus Life Sciences by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 204,137 shares of the company’s stock valued at $1,023,000 after purchasing an additional 3,710 shares during the last quarter. Northern Trust Corp lifted its position in shares of TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock worth $161,000 after buying an additional 5,936 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of TriSalus Life Sciences in the 4th quarter valued at about $67,000. Walleye Capital LLC bought a new stake in shares of TriSalus Life Sciences during the 3rd quarter valued at about $66,000. Finally, Virtu Financial LLC bought a new stake in shares of TriSalus Life Sciences during the 3rd quarter valued at about $92,000. 2.58% of the stock is owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.